IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer
Cisplatin-based chemotherapy is the paradigm of non-small-cell lung cancer (NSCLC) treatment; however, it also induces de novo DNA-hypermethylation, a process that may be involved in the development of drug-resistant phenotypes by inactivating genes required for drug-cytotoxicity. By using an expres...
Saved in:
Published in | Oncogene Vol. 29; no. 11; pp. 1681 - 1690 |
---|---|
Main Authors | , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Basingstoke
Nature Publishing Group
18.03.2010
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Cisplatin-based chemotherapy is the paradigm of non-small-cell lung cancer (NSCLC) treatment; however, it also induces de novo DNA-hypermethylation, a process that may be involved in the development of drug-resistant phenotypes by inactivating genes required for drug-cytotoxicity. By using an expression microarray analysis, we aimed to identify those genes reactivated in a set of two cisplatin (CDDP) resistant and sensitive NSCLC cell lines after epigenetic treatment. Gene expression, promoter methylation and CDDP-chemoresponse were further analyzed in three matched sets of sensitive/resistant cell lines, 23 human cancer cell lines and 36 NSCLC specimens. Results revealed specific silencing by promoter hypermethylation of IGFBP-3 in CDDP resistant cells, whereas IGFBP-3 siRNA interference, induced resistance to CDDP in sensitive cells (P<0.001). In addition, we found a strong correlation between methylation status and CDDP response in tumor specimens (P<0.001). Thus, stage I patients, whose tumors harbor an unmethylated promoter, had a trend towards increased disease-free survival (DFS). We report that a loss of IGFBP-3 expression, mediated by promoter-hypermethylation, results in a reduction of tumor cell sensitivity to cisplatin in NSCLC. Basal methylation status of IGFBP-3 before treatment may be a clinical biomarker and a predictor of the chemotherapy outcome, helping to identify patients who are most likely to benefit from CDDP therapy alone or in combination with epigenetic treatment. |
---|---|
AbstractList | Cisplatin-based chemotherapy is the paradigm of non-small-cell lung cancer (NSCLC) treatment; however, it also induces de novo DNA-hypermethylation, a process that may be involved in the development of drug-resistant phenotypes by inactivating genes required for drug-cytotoxicity. By using an expression microarray analysis, we aimed to identify those genes reactivated in a set of two cisplatin (CDDP) resistant and sensitive NSCLC cell lines after epigenetic treatment. Gene expression, promoter methylation and CDDP-chemoresponse were further analyzed in three matched sets of sensitive/resistant cell lines, 23 human cancer cell lines and 36 NSCLC specimens. Results revealed specific silencing by promoter hypermethylation of IGFBP-3 in CDDP resistant cells, whereas IGFBP-3 siRNA interference, induced resistance to CDDP in sensitive cells (P<0.001). In addition, we found a strong correlation between methylation status and CDDP response in tumor specimens (P<0.001). Thus, stage I patients, whose tumors harbor an unmethylated promoter, had a trend towards increased disease-free survival (DFS). We report that a loss of IGFBP-3 expression, mediated by promoter-hypermethylation, results in a reduction of tumor cell sensitivity to cisplatin in NSCLC. Basal methylation status of IGFBP-3 before treatment may be a clinical biomarker and a predictor of the chemotherapy outcome, helping to identify patients who are most likely to benefit from CDDP therapy alone or in combination with epigenetic treatment. Cisplatin-based chemotherapy is the paradigm of non-small-cell lung cancer (NSCLC) treatment; however, it also induces de novo DNA-hypermethylation, a process that may be involved in the development of drug-resistant phenotypes by inactivating genes required for drug-cytotoxicity. By using an expression microarray analysis, we aimed to identify those genes reactivatedinasetoftwocisplatin (CDDP) resistant and sensitive NSCLC cell lines after epigenetic treatment. Gene expression, promoter methylation and CDDP-chemoresponse were further analyzed in three matched sets of sensitive/resistant cell lines, 23 human cancer cell lines and 36 NSCLC specimens. Results revealed specific silencing by promoter hypermethylation of IGFBP-3 in CDDP resistant cells, whereas IGFBP-3 siRNA interference, induced resistance to CDDP in sensitive cells (P < 0.001). In addition, we found a strong correlation between methylation status and CDDP response in tumor specimens (P < 0.001). Thus, stage I patients, whose tumors harbor an unmethylated promoter, had a trend towards increased disease-free survival (DFS). We report that a loss of IGFBP-3 expression, mediated by promoter-hypermethylation, results in a reduction of tumor cell sensitivity to cisplatin in NSCLC. Basal methylation status of IGFBP-3 before treatment may be a clinical biomarker and a predictor of the chemotherapy outcome, helping to identify patients who are most likely to benefit from CDDP therapy alone or in combination with epigenetic treatment. Oncogene (2010) 29, 1681-1690; doi: 10.1038/onc.2009.454; published online 21 December 2009 Keywords: CDDP-resistance; IGFBP-3; NSCLC; hypermethylation Cisplatin-based chemotherapy is the paradigm of non-small-cell lung cancer (NSCLC) treatment; however, it also induces de novo DNA-hypermethylation, a process that may be involved in the development of drug-resistant phenotypes by inactivating genes required for drug-cytotoxicity. By using an expression microarray analysis, we aimed to identify those genes reactivated in a set of two cisplatin (CDDP) resistant and sensitive NSCLC cell lines after epigenetic treatment. Gene expression, promoter methylation and CDDP-chemoresponse were further analyzed in three matched sets of sensitive/resistant cell lines, 23 human cancer cell lines and 36 NSCLC specimens. Results revealed specific silencing by promoter hypermethylation of IGFBP-3 in CDDP resistant cells, whereas IGFBP-3 siRNA interference, induced resistance to CDDP in sensitive cells (P<0.001). In addition, we found a strong correlation between methylation status and CDDP response in tumor specimens (P<0.001). Thus, stage I patients, whose tumors harbor an unmethylated promoter, had a trend towards increased disease-free survival (DFS). We report that a loss of IGFBP-3 expression, mediated by promoter-hypermethylation, results in a reduction of tumor cell sensitivity to cisplatin in NSCLC. Basal methylation status of IGFBP-3 before treatment may be a clinical biomarker and a predictor of the chemotherapy outcome, helping to identify patients who are most likely to benefit from CDDP therapy alone or in combination with epigenetic treatment. [PUBLICATION ABSTRACT] Cisplatin-based chemotherapy is the paradigm of non-small-cell lung cancer (NSCLC) treatment; however, it also induces de novo DNA-hypermethylation, a process that may be involved in the development of drug-resistant phenotypes by inactivating genes required for drug-cytotoxicity. By using an expression microarray analysis, we aimed to identify those genes reactivatedinasetoftwocisplatin (CDDP) resistant and sensitive NSCLC cell lines after epigenetic treatment. Gene expression, promoter methylation and CDDP-chemoresponse were further analyzed in three matched sets of sensitive/resistant cell lines, 23 human cancer cell lines and 36 NSCLC specimens. Results revealed specific silencing by promoter hypermethylation of IGFBP-3 in CDDP resistant cells, whereas IGFBP-3 siRNA interference, induced resistance to CDDP in sensitive cells (P < 0.001). In addition, we found a strong correlation between methylation status and CDDP response in tumor specimens (P < 0.001). Thus, stage I patients, whose tumors harbor an unmethylated promoter, had a trend towards increased disease-free survival (DFS). We report that a loss of IGFBP-3 expression, mediated by promoter-hypermethylation, results in a reduction of tumor cell sensitivity to cisplatin in NSCLC. Basal methylation status of IGFBP-3 before treatment may be a clinical biomarker and a predictor of the chemotherapy outcome, helping to identify patients who are most likely to benefit from CDDP therapy alone or in combination with epigenetic treatment. Cisplatin-based chemotherapy is the paradigm of non-small-cell lung cancer (NSCLC) treatment; however, it also induces de novo DNA-hypermethylation, a process that may be involved in the development of drug-resistant phenotypes by inactivating genes required for drug-cytotoxicity. By using an expression microarray analysis, we aimed to identify those genes reactivated in a set of two cisplatin (CDDP) resistant and sensitive NSCLC cell lines after epigenetic treatment. Gene expression, promoter methylation and CDDP-chemoresponse were further analyzed in three matched sets of sensitive/resistant cell lines, 23 human cancer cell lines and 36 NSCLC specimens. Results revealed specific silencing by promoter hypermethylation of IGFBP-3 in CDDP resistant cells, whereas IGFBP-3 siRNA interference, induced resistance to CDDP in sensitive cells (P<0.001). In addition, we found a strong correlation between methylation status and CDDP response in tumor specimens (P<0.001). Thus, stage I patients, whose tumors harbor an unmethylated promoter, had a trend towards increased disease-free survival (DFS). We report that a loss of IGFBP-3 expression, mediated by promoter-hypermethylation, results in a reduction of tumor cell sensitivity to cisplatin in NSCLC. Basal methylation status of IGFBP-3 before treatment may be a clinical biomarker and a predictor of the chemotherapy outcome, helping to identify patients who are most likely to benefit from CDDP therapy alone or in combination with epigenetic treatment. |
Audience | Academic |
Author | LOPEZ-RIOS, F PAZ-ARES, L IBANEZ DE CACERES, I DE CASTROCARPENO, J NISTAL, M CORTES-SEMPERE, M PERONA, R MACHADO-PINILLA, R BELDA-INIESTA, C MORATILLA, C MANGUAN-GARCIA, C RODRIGUEZ-FANJUL, V CEJAS, P |
Author_xml | – sequence: 1 givenname: I surname: IBANEZ DE CACERES fullname: IBANEZ DE CACERES, I organization: Oncology Research Laboratory, Research Unit, FIB-La Paz University Hospital, Madrid, Spain – sequence: 2 givenname: M surname: CORTES-SEMPERE fullname: CORTES-SEMPERE, M organization: Instituto de Investigaciones Biomedicas CSIC/UAM, Translational Oncology Unit CSIC/H La Paz, Madrid, Spain – sequence: 3 givenname: M surname: NISTAL fullname: NISTAL, M organization: Department of Pathology, La Paz University Hospital, Madrid, Spain – sequence: 4 givenname: C surname: BELDA-INIESTA fullname: BELDA-INIESTA, C organization: Department of Medical Oncology, La Paz University Hospital, Translational Oncology Unit CSIC/H La Paz, Madrid, Spain – sequence: 5 givenname: R surname: PERONA fullname: PERONA, R organization: Instituto de Investigaciones Biomedicas CSIC/UAM, Translational Oncology Unit CSIC/H La Paz, Madrid, Spain – sequence: 6 givenname: C surname: MORATILLA fullname: MORATILLA, C organization: Instituto de Investigaciones Biomedicas CSIC/UAM, Translational Oncology Unit CSIC/H La Paz, Madrid, Spain – sequence: 7 givenname: R surname: MACHADO-PINILLA fullname: MACHADO-PINILLA, R organization: Instituto de Investigaciones Biomedicas CSIC/UAM, Translational Oncology Unit CSIC/H La Paz, Madrid, Spain – sequence: 8 givenname: V surname: RODRIGUEZ-FANJUL fullname: RODRIGUEZ-FANJUL, V organization: Instituto de Investigaciones Biomedicas CSIC/UAM, Translational Oncology Unit CSIC/H La Paz, Madrid, Spain – sequence: 9 givenname: C surname: MANGUAN-GARCIA fullname: MANGUAN-GARCIA, C organization: Instituto de Investigaciones Biomedicas CSIC/UAM, Translational Oncology Unit CSIC/H La Paz, Madrid, Spain – sequence: 10 givenname: P surname: CEJAS fullname: CEJAS, P organization: Department of Medical Oncology, La Paz University Hospital, Translational Oncology Unit CSIC/H La Paz, Madrid, Spain – sequence: 11 givenname: F surname: LOPEZ-RIOS fullname: LOPEZ-RIOS, F organization: Department of Pathology, 12 de Octubre Hospital, Madrid, Spain – sequence: 12 givenname: L surname: PAZ-ARES fullname: PAZ-ARES, L organization: Department of Medical Oncology, 12 de Octubre Hospital, Madrid, Spain – sequence: 13 givenname: J surname: DE CASTROCARPENO fullname: DE CASTROCARPENO, J organization: Department of Medical Oncology, La Paz University Hospital, Translational Oncology Unit CSIC/H La Paz, Madrid, Spain |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22752816$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/20023704$$D View this record in MEDLINE/PubMed |
BookMark | eNqFks9rFDEUx4NU7Hb15lkGRbw4a_Lya3KsxdZCQQ96Dtn82KbMZNZkRtj_3gxdLYpicngk-byX7-N9z9BJGpNH6DnBG4Jp925MdgMYqw3j7BFaESZFy7liJ2iFFcetAgqn6KyUO4yxVBieoNPKA5WYrdDu-ury_eeWNreHvc-Dn24PvZnimFrnc_zuXeN8iDb6ZA_N4F00ky-NjWW_YKnJvsQymWR9U09VWlsG0_et9X3f9HPaNXZ5zE_R42D64p8d4xp9vfzw5eJje_Pp6vri_Ka1nMDUhi020rktDSCIClhyy2WHDXUcOAWJqxqjOiAUrA2c1obCVnkjHHQCnKVr9Oa-7j6P32ZfJj3EsogxyY9z0ZIxQUQn5P9JSjllsoY1evUHeTfOOdU2NAhGaCdBqkq9_CcFkgqhKH4otTO91zGFccrGLh_rc6iLg6CsUpu_UHU7P0Rbxx9ivf8t4e19gs1jKdkHvc9xMPmgCdaLS3R1iV5coqtLKv7iKHXe1pn-gn_aogKvj4Ap1vQh1xnG8sCB5NARQX8AXYfDsg |
CODEN | ONCNES |
CitedBy_id | crossref_primary_10_1016_j_biopha_2014_12_016 crossref_primary_10_3390_cancers3011426 crossref_primary_10_3390_cells11030468 crossref_primary_10_18632_oncotarget_25326 crossref_primary_10_1186_s12929_020_00651_0 crossref_primary_10_1038_nrc3720 crossref_primary_10_1016_j_talanta_2024_125895 crossref_primary_10_1371_journal_pone_0112880 crossref_primary_10_4161_epi_28601 crossref_primary_10_1155_2022_6468773 crossref_primary_10_1186_s13073_014_0066_6 crossref_primary_10_1016_j_semcancer_2017_09_005 crossref_primary_10_1016_j_trsl_2015_11_003 crossref_primary_10_1016_j_biopha_2021_112202 crossref_primary_10_2217_epi_15_84 crossref_primary_10_3390_pharmaceutics14061143 crossref_primary_10_1371_journal_pone_0022635 crossref_primary_10_3390_biomedicines12030563 crossref_primary_10_1016_j_bcp_2023_115498 crossref_primary_10_1093_bfgp_elw010 crossref_primary_10_3390_cancers14122918 crossref_primary_10_3390_cancers14194562 crossref_primary_10_3389_fonc_2020_00764 crossref_primary_10_1016_j_gmbhs_2012_04_010 crossref_primary_10_1007_s13167_022_00300_6 crossref_primary_10_1038_srep42573 crossref_primary_10_3389_fimmu_2023_1122352 crossref_primary_10_1007_s12079_015_0294_6 crossref_primary_10_3390_ijms24054804 crossref_primary_10_3390_cells12030405 crossref_primary_10_1002_ijc_25951 crossref_primary_10_1155_2016_4369431 crossref_primary_10_3892_ijo_2012_1464 crossref_primary_10_1002_adma_202308977 crossref_primary_10_1101_cshperspect_a038000 crossref_primary_10_3390_cancers12040786 crossref_primary_10_1016_j_canlet_2020_05_006 crossref_primary_10_1016_j_ygeno_2020_12_045 crossref_primary_10_1016_j_ijrobp_2011_06_1999 crossref_primary_10_1002_jcb_27786 crossref_primary_10_1007_s13402_019_00465_9 crossref_primary_10_3390_cancers14040961 crossref_primary_10_1007_s12325_011_0047_8 crossref_primary_10_1155_2017_9620870 crossref_primary_10_1186_s13148_021_01044_2 crossref_primary_10_1016_j_gene_2015_06_028 crossref_primary_10_1016_j_trsl_2018_06_005 crossref_primary_10_1155_2015_638526 crossref_primary_10_1016_j_semcancer_2020_12_014 crossref_primary_10_1371_journal_pone_0104285 crossref_primary_10_3892_ijo_2014_2733 crossref_primary_10_1016_j_semcancer_2020_12_011 crossref_primary_10_1093_carcin_bgu129 crossref_primary_10_1186_s13000_020_01054_3 crossref_primary_10_1186_s13148_021_01149_8 crossref_primary_10_1186_s13023_014_0103_y crossref_primary_10_4161_15592294_2014_971626 crossref_primary_10_1371_journal_pone_0104249 crossref_primary_10_1371_journal_pone_0049819 crossref_primary_10_1002_cncr_28411 crossref_primary_10_1155_2018_5416923 crossref_primary_10_3892_ol_2017_6019 crossref_primary_10_1007_s12272_021_01312_y crossref_primary_10_1038_nbt_1678 crossref_primary_10_3389_fcell_2021_634512 crossref_primary_10_5005_jp_journals_10085_5106 crossref_primary_10_2147_IJN_S271976 crossref_primary_10_3390_cells9051261 crossref_primary_10_1186_s13073_018_0562_1 crossref_primary_10_3390_antiox9060468 crossref_primary_10_1038_onc_2012_146 crossref_primary_10_1038_nrg3270 crossref_primary_10_1007_s13277_012_0352_0 crossref_primary_10_1002_jcp_27520 crossref_primary_10_3390_cells11223533 crossref_primary_10_3390_microarrays4030324 crossref_primary_10_3390_biology12040498 crossref_primary_10_3390_biom12101365 crossref_primary_10_1593_tlo_12256 crossref_primary_10_1186_s12885_023_10832_3 crossref_primary_10_1016_j_gendis_2018_06_003 crossref_primary_10_1007_s40495_019_00201_9 crossref_primary_10_1096_fj_201600427R crossref_primary_10_1371_journal_pone_0092853 crossref_primary_10_1016_j_cca_2017_01_017 crossref_primary_10_1038_labinvest_2015_123 crossref_primary_10_1186_s13046_021_01898_7 crossref_primary_10_1080_15592294_2018_1436364 crossref_primary_10_1038_nm_2305 crossref_primary_10_1016_j_labcli_2014_04_004 crossref_primary_10_1016_j_pan_2020_07_406 crossref_primary_10_1186_1471_2164_15_1079 crossref_primary_10_1586_erm_13_36 crossref_primary_10_1124_pr_111_005637 crossref_primary_10_1158_1541_7786_MCR_16_0390 |
Cites_doi | 10.1016/S0002-9440(10)65102-4 10.1038/sj.bjc.6601956 10.1002/jcb.20558 10.1002/ijc.1466 10.1038/sj.onc.1209364 10.1056/NEJMra0802714 10.1158/1078-0432.CCR-04-2455 10.1158/1078-0432.CCR-07-0722 10.1158/0008-5472.CAN-06-1684 10.1038/sj.bjc.6604932 10.1002/ijc.23721 10.1074/jbc.272.18.12181 10.1038/377646a0 10.2165/00002018-199513040-00003 10.1158/1535-7163.MCT-08-0642 10.1186/1476-4598-3-16 10.1146/annurev.med.53.082901.103929 10.1016/S1383-5742(96)00051-8 10.1016/S0065-230X(04)91004-4 10.1038/nm0795-686 10.1186/1476-4598-3-14 10.1038/sj.onc.1208955 10.1038/sj.bjc.6604180 10.3322/CA.2007.0010 10.1016/j.ygyno.2004.06.018 10.1038/sj.onc.1202540 10.1016/S0065-230X(08)60702-2 10.1158/0008-5472.CAN-05-3365 10.1111/j.1525-1438.2006.00299.x 10.1158/1078-0432.CCR-06-2077 10.1038/sj.bjc.6603767 10.1371/journal.pone.0003077 |
ContentType | Journal Article |
Copyright | 2015 INIST-CNRS COPYRIGHT 2010 Nature Publishing Group Copyright Nature Publishing Group Mar 18, 2010 Macmillan Publishers Limited 2010. |
Copyright_xml | – notice: 2015 INIST-CNRS – notice: COPYRIGHT 2010 Nature Publishing Group – notice: Copyright Nature Publishing Group Mar 18, 2010 – notice: Macmillan Publishers Limited 2010. |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7TM 7TO 7U9 7X7 7XB 88A 88E 8AO 8C1 8FD 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K9. LK8 M0S M1P M2O M7P MBDVC P64 PQEST PQQKQ PQUKI PRINS Q9U RC3 7X8 |
DOI | 10.1038/onc.2009.454 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni Edition) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials Biological Science Collection ProQuest Central ProQuest Natural Science Collection ProQuest One Community College ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) ProQuest Biological Science Collection Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) ProQuest research library Biological Science Database Research Library (Corporate) Biotechnology and BioEngineering Abstracts ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic Genetics Abstracts MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Research Library Prep ProQuest Central Student Oncogenes and Growth Factors Abstracts Technology Research Database ProQuest Central Essentials Nucleic Acids Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central China ProQuest Biology Journals (Alumni Edition) ProQuest Central Genetics Abstracts Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Medical Library (Alumni) ProQuest Public Health Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Engineering Research Database ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | Genetics Abstracts Research Library Prep Research Library Prep MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Biology |
EISSN | 1476-5594 |
EndPage | 1690 |
ExternalDocumentID | 1987848771 A222252634 10_1038_onc_2009_454 20023704 22752816 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GeographicLocations | Spain |
GeographicLocations_xml | – name: Spain |
GroupedDBID | --- -Q- .55 .GJ 08R 0R~ 123 29N 2WC 36B 39C 3O- 3V. 4.4 406 53G 5RE 70F 7X7 88A 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8G5 8R4 8R5 AADWK AANZL AAPBV AATNV AAUGY AAWBL AAYFA AAYJO AAZLF ABAWZ ABDBF ABEFU ABGIJ ABLJU ABPTK ABUWG ACBMV ACBRV ACBYP ACGFO ACGFS ACIGE ACKTT ACMJI ACPRK ACRQY ACTTH ACVWB ADBBV ADFRT ADHDB ADMDM ADQMX ADYYL AEDAW AEFTE AEJRE AENEX AEVLU AEXYK AFFNX AFKRA AFNRJ AFSHS AGEZK AGGBP AGHAI AHMBA AHSBF AILAN AJCLW AJDOV AJRNO ALFFA ALMA_UNASSIGNED_HOLDINGS AMRJV AMYLF ASPBG AVWKF AXYYD AZFZN AZQEC B0M BAWUL BBNVY BENPR BHPHI BKKNO BPHCQ BVXVI CAG CCPQU COF CS3 DIK DNIVK DPUIP DU5 DWQXO E3Z EAD EAP EBC EBD EBLON EBS EE. EIOEI EJD EMB EMK EMOBN EPL ESX F5P FDQFY FEDTE FERAY FIZPM FRP FSGXE FYUFA GNUQQ GUQSH HCIFZ HZ~ IAO IHR INH INR IQODW ITC IWAJR JSO JZLTJ KQ8 L7B LK8 M0L M1P M2O M7P N9A NAO NQJWS NXXTH NYICJ O9- OK1 OVD P2P PQQKQ PROAC PSQYO Q2X RNS RNT RNTTT SNX SNYQT SOHCF SRMVM SV3 SWTZT TAOOD TBHMF TDRGL TEORI TR2 TSG TUS UDS UKHRP W2D WH7 X7M ZA5 ZXP ~8M ABAKF ABJNI ABZZP ACAOD ACZOJ AEMSY AFBBN AGQEE ALIPV CGR CUY CVF ECM EIF HMCUK HVGLF NPM AAYXX CITATION FIGPU 7TM 7TO 7U9 7XB 8FD 8FK FR3 H94 K9. MBDVC P64 PQEST PQUKI PRINS Q9U RC3 7X8 |
ID | FETCH-LOGICAL-c512t-fb0a7ddb3f2619f075c5780a3d5253270defa982132ccf53079fb9ea6d2862dc3 |
IEDL.DBID | 7X7 |
ISSN | 0950-9232 |
IngestDate | Sat Aug 17 03:06:57 EDT 2024 Fri Aug 16 04:28:27 EDT 2024 Fri Sep 13 05:00:21 EDT 2024 Fri Sep 13 03:11:34 EDT 2024 Thu Feb 22 23:48:42 EST 2024 Fri Feb 02 04:12:11 EST 2024 Fri Sep 27 02:37:13 EDT 2024 Sat Sep 28 07:46:32 EDT 2024 Sun Oct 22 16:04:58 EDT 2023 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 11 |
Keywords | Antineoplastic agent Lung disease NSCLC Respiratory disease Deficiency hypermethylation Malignant tumor CDDP-resistance non-small cell lung carcinoma Carcinogenesis Cisplatin Resistance IGFBP-3 Bronchus disease Methylation Cancer |
Language | English |
License | CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c512t-fb0a7ddb3f2619f075c5780a3d5253270defa982132ccf53079fb9ea6d2862dc3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://doi.org/10.1038/onc.2009.454 |
PMID | 20023704 |
PQID | 227366930 |
PQPubID | 36330 |
PageCount | 10 |
ParticipantIDs | proquest_miscellaneous_744616867 proquest_miscellaneous_733534773 proquest_journals_2641387279 proquest_journals_227366930 gale_infotracmisc_A222252634 gale_infotracacademiconefile_A222252634 crossref_primary_10_1038_onc_2009_454 pubmed_primary_20023704 pascalfrancis_primary_22752816 |
PublicationCentury | 2000 |
PublicationDate | 2010-03-18 |
PublicationDateYYYYMMDD | 2010-03-18 |
PublicationDate_xml | – month: 03 year: 2010 text: 2010-03-18 day: 18 |
PublicationDecade | 2010 |
PublicationPlace | Basingstoke |
PublicationPlace_xml | – name: Basingstoke – name: England – name: New York |
PublicationTitle | Oncogene |
PublicationTitleAlternate | Oncogene |
PublicationYear | 2010 |
Publisher | Nature Publishing Group |
Publisher_xml | – name: Nature Publishing Group |
References | SB Baylin (BFonc2009454_CR3) 1998; 72 M Esteller (BFonc2009454_CR10) 1999; 59 V Levina (BFonc2009454_CR20) 2008; 3 I Ibanez de Caceres (BFonc2009454_CR16) 2006; 66 BFonc2009454_CR1 P Zhang (BFonc2009454_CR42) 2004; 3 YS Chang (BFonc2009454_CR7) 2002; 8 MR Morris (BFonc2009454_CR28) 2008; 98 S Zochbauer-Muller (BFonc2009454_CR43) 2001; 61 R Rajah (BFonc2009454_CR34) 1997; 272 S Koul (BFonc2009454_CR19) 2004; 3 A Wiley (BFonc2009454_CR40) 2006; 16 RS Herbst (BFonc2009454_CR14) 2008; 359 A Jemal (BFonc2009454_CR17) 2008; 58 A Merlo (BFonc2009454_CR25) 1995; 1 PA Marks (BFonc2009454_CR23) 2004; 91 J Nyce (BFonc2009454_CR29) 1989; 49 JH Yoon (BFonc2009454_CR41) 2001; 94 EK Baker (BFonc2009454_CR2) 2005; 24 G Strathdee (BFonc2009454_CR39) 1999; 18 SA Belinsky (BFonc2009454_CR4) 2003; 63 M Guix (BFonc2009454_CR13) 2008; 118 AS Perry (BFonc2009454_CR31) 2007; 96 MM Gottesman (BFonc2009454_CR12) 2002; 53 IB Roninson (BFonc2009454_CR36) 2003; 63 SS Huang (BFonc2009454_CR15) 2005; 96 L Buckbinder (BFonc2009454_CR5) 1995; 377 B Leyland-Jones (BFonc2009454_CR21) 1999; 155 JW Nyce (BFonc2009454_CR30) 1997; 386 JA Plumb (BFonc2009454_CR33) 2000; 60 YS Chang (BFonc2009454_CR8) 2002; 8 S Chattopadhyay (BFonc2009454_CR9) 2006; 25 F Morgillo (BFonc2009454_CR26) 2007; 13 C Plasencia (BFonc2009454_CR32) 2006; 29 D Katsaros (BFonc2009454_CR18) 2004; 94 AL Carvalho (BFonc2009454_CR6) 2008; 14 F Morgillo (BFonc2009454_CR27) 2006; 66 DW Shen (BFonc2009454_CR37) 2004; 91 N Steele (BFonc2009454_CR38) 2009; 100 RF Riedel (BFonc2009454_CR35) 2008; 7 EM Gosepath (BFonc2009454_CR11) 2008; 123 PB Makarla (BFonc2009454_CR22) 2005; 11 MJ McKeage (BFonc2009454_CR24) 1995; 13 |
References_xml | – volume: 8 start-page: 3796 year: 2002 ident: BFonc2009454_CR7 publication-title: Clin Cancer Res contributor: fullname: YS Chang – volume: 155 start-page: 77 year: 1999 ident: BFonc2009454_CR21 publication-title: Am J Pathol doi: 10.1016/S0002-9440(10)65102-4 contributor: fullname: B Leyland-Jones – volume: 91 start-page: 270 year: 2004 ident: BFonc2009454_CR37 publication-title: Br J Cancer doi: 10.1038/sj.bjc.6601956 contributor: fullname: DW Shen – volume: 63 start-page: 7089 year: 2003 ident: BFonc2009454_CR4 publication-title: Cancer Res contributor: fullname: SA Belinsky – volume: 96 start-page: 447 year: 2005 ident: BFonc2009454_CR15 publication-title: J Cell Biochem doi: 10.1002/jcb.20558 contributor: fullname: SS Huang – volume: 94 start-page: 212 year: 2001 ident: BFonc2009454_CR41 publication-title: Int J Cancer doi: 10.1002/ijc.1466 contributor: fullname: JH Yoon – volume: 25 start-page: 3335 year: 2006 ident: BFonc2009454_CR9 publication-title: Oncogene doi: 10.1038/sj.onc.1209364 contributor: fullname: S Chattopadhyay – volume: 359 start-page: 1367 year: 2008 ident: BFonc2009454_CR14 publication-title: N Engl J Med doi: 10.1056/NEJMra0802714 contributor: fullname: RS Herbst – volume: 49 start-page: 5829 year: 1989 ident: BFonc2009454_CR29 publication-title: Cancer Res contributor: fullname: J Nyce – volume: 11 start-page: 5365 year: 2005 ident: BFonc2009454_CR22 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-04-2455 contributor: fullname: PB Makarla – volume: 14 start-page: 97 year: 2008 ident: BFonc2009454_CR6 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-07-0722 contributor: fullname: AL Carvalho – volume: 66 start-page: 10100 year: 2006 ident: BFonc2009454_CR27 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-06-1684 contributor: fullname: F Morgillo – volume: 100 start-page: 758 year: 2009 ident: BFonc2009454_CR38 publication-title: Br J Cancer doi: 10.1038/sj.bjc.6604932 contributor: fullname: N Steele – ident: BFonc2009454_CR1 – volume: 123 start-page: 2013 year: 2008 ident: BFonc2009454_CR11 publication-title: Int J Cancer doi: 10.1002/ijc.23721 contributor: fullname: EM Gosepath – volume: 272 start-page: 12181 year: 1997 ident: BFonc2009454_CR34 publication-title: J Biol Chem doi: 10.1074/jbc.272.18.12181 contributor: fullname: R Rajah – volume: 377 start-page: 646 year: 1995 ident: BFonc2009454_CR5 publication-title: Nature doi: 10.1038/377646a0 contributor: fullname: L Buckbinder – volume: 13 start-page: 228 year: 1995 ident: BFonc2009454_CR24 publication-title: Drug Saf doi: 10.2165/00002018-199513040-00003 contributor: fullname: MJ McKeage – volume: 7 start-page: 3141 year: 2008 ident: BFonc2009454_CR35 publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-08-0642 contributor: fullname: RF Riedel – volume: 61 start-page: 249 year: 2001 ident: BFonc2009454_CR43 publication-title: Cancer Res contributor: fullname: S Zochbauer-Muller – volume: 3 start-page: 16 year: 2004 ident: BFonc2009454_CR19 publication-title: Mol Cancer doi: 10.1186/1476-4598-3-16 contributor: fullname: S Koul – volume: 63 start-page: 2705 year: 2003 ident: BFonc2009454_CR36 publication-title: Cancer Res contributor: fullname: IB Roninson – volume: 53 start-page: 615 year: 2002 ident: BFonc2009454_CR12 publication-title: Annu Rev Med doi: 10.1146/annurev.med.53.082901.103929 contributor: fullname: MM Gottesman – volume: 386 start-page: 153 year: 1997 ident: BFonc2009454_CR30 publication-title: Mutat Res doi: 10.1016/S1383-5742(96)00051-8 contributor: fullname: JW Nyce – volume: 91 start-page: 137 year: 2004 ident: BFonc2009454_CR23 publication-title: Adv Cancer Res doi: 10.1016/S0065-230X(04)91004-4 contributor: fullname: PA Marks – volume: 1 start-page: 686 year: 1995 ident: BFonc2009454_CR25 publication-title: Nat Med doi: 10.1038/nm0795-686 contributor: fullname: A Merlo – volume: 3 start-page: 14 year: 2004 ident: BFonc2009454_CR42 publication-title: Mol Cancer doi: 10.1186/1476-4598-3-14 contributor: fullname: P Zhang – volume: 24 start-page: 8061 year: 2005 ident: BFonc2009454_CR2 publication-title: Oncogene doi: 10.1038/sj.onc.1208955 contributor: fullname: EK Baker – volume: 118 start-page: 2609 year: 2008 ident: BFonc2009454_CR13 publication-title: J Clin Invest contributor: fullname: M Guix – volume: 29 start-page: 225 year: 2006 ident: BFonc2009454_CR32 publication-title: Int J Oncol contributor: fullname: C Plasencia – volume: 98 start-page: 496 year: 2008 ident: BFonc2009454_CR28 publication-title: Br J Cancer doi: 10.1038/sj.bjc.6604180 contributor: fullname: MR Morris – volume: 60 start-page: 6039 year: 2000 ident: BFonc2009454_CR33 publication-title: Cancer Res contributor: fullname: JA Plumb – volume: 58 start-page: 71 year: 2008 ident: BFonc2009454_CR17 publication-title: CA Cancer J Clin doi: 10.3322/CA.2007.0010 contributor: fullname: A Jemal – volume: 8 start-page: 3669 year: 2002 ident: BFonc2009454_CR8 publication-title: Clin Cancer Res contributor: fullname: YS Chang – volume: 94 start-page: 685 year: 2004 ident: BFonc2009454_CR18 publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2004.06.018 contributor: fullname: D Katsaros – volume: 18 start-page: 2335 year: 1999 ident: BFonc2009454_CR39 publication-title: Oncogene doi: 10.1038/sj.onc.1202540 contributor: fullname: G Strathdee – volume: 72 start-page: 141 year: 1998 ident: BFonc2009454_CR3 publication-title: Adv Cancer Res doi: 10.1016/S0065-230X(08)60702-2 contributor: fullname: SB Baylin – volume: 66 start-page: 5021 year: 2006 ident: BFonc2009454_CR16 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-05-3365 contributor: fullname: I Ibanez de Caceres – volume: 16 start-page: 210 year: 2006 ident: BFonc2009454_CR40 publication-title: Int J Gynecol Cancer doi: 10.1111/j.1525-1438.2006.00299.x contributor: fullname: A Wiley – volume: 13 start-page: 2795 year: 2007 ident: BFonc2009454_CR26 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-06-2077 contributor: fullname: F Morgillo – volume: 96 start-page: 1587 year: 2007 ident: BFonc2009454_CR31 publication-title: Br J Cancer doi: 10.1038/sj.bjc.6603767 contributor: fullname: AS Perry – volume: 3 start-page: e3077 year: 2008 ident: BFonc2009454_CR20 publication-title: PLoS ONE doi: 10.1371/journal.pone.0003077 contributor: fullname: V Levina – volume: 59 start-page: 793 year: 1999 ident: BFonc2009454_CR10 publication-title: Cancer Res contributor: fullname: M Esteller |
SSID | ssj0007902 |
Score | 2.368009 |
Snippet | Cisplatin-based chemotherapy is the paradigm of non-small-cell lung cancer (NSCLC) treatment; however, it also induces de novo DNA-hypermethylation, a process... |
SourceID | proquest gale crossref pubmed pascalfrancis |
SourceType | Aggregation Database Index Database |
StartPage | 1681 |
SubjectTerms | Antineoplastic Agents - pharmacology Azacitidine - pharmacology Base Sequence Binding proteins Biological and medical sciences Cancer therapies Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - metabolism Carcinoma, Non-Small-Cell Lung - pathology Cell Line, Tumor Cell physiology Cell Survival - drug effects Cell transformation and carcinogenesis. Action of oncogenes and antioncogenes Chemotherapy Cisplatin Cisplatin - pharmacology Complications and side effects Cytotoxicity Deoxyribonucleic acid DNA DNA damage DNA methylation DNA Methylation - drug effects DNA microarrays Dosage and administration Drug resistance Drug Resistance, Neoplasm - genetics Drug therapy Epigenetics Fundamental and applied biological sciences. Psychology Gene expression Gene Expression Regulation, Neoplastic - drug effects Genetic aspects Genetics HeLa Cells HT29 Cells Humans Hydroxamic Acids - pharmacology Insulin-Like Growth Factor Binding Protein 3 - deficiency Insulin-Like Growth Factor Binding Protein 3 - genetics Insulin-like growth factor-binding protein 3 Kaplan-Meier Estimate Lung cancer Lung cancer, Non-small cell Lung Neoplasms - genetics Lung Neoplasms - metabolism Lung Neoplasms - pathology Medical sciences Molecular and cellular biology Non-small cell lung carcinoma Oligonucleotide Array Sequence Analysis Patients Phenotypes Physiological aspects Pneumology Promoter Regions, Genetic - genetics Reverse Transcriptase Polymerase Chain Reaction RNA Interference siRNA Small cell lung carcinoma Tumor cell lines Tumor Cells, Cultured Tumors Tumors of the respiratory system and mediastinum |
Title | IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer |
URI | https://www.ncbi.nlm.nih.gov/pubmed/20023704 https://www.proquest.com/docview/227366930/abstract/ https://www.proquest.com/docview/2641387279/abstract/ https://search.proquest.com/docview/733534773 https://search.proquest.com/docview/744616867 |
Volume | 29 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwED-NTXxICEGBETYqP4B4surYjp08oa1aN5CYJsSkvkWxHcNDSbu2Q9p_z12SFlWCvUSKzslZvvPd7-yzD-B95mtEsc7wNArFdR4Mr3IVeaVE0Fp4gTTKtrg0F9f6yzSb7sH55iwMpVVubGJrqMPc0xr5SKKfNVS3b1Q5WgTw69GnxQ2n8lG0zdrX0ngAB6lEVIGKbafbyEvYLvkQ4YTgiGhknwEvVD6aN767tVJnesc39Rb66aJa4WjFrszF_3Fo648mz-FZDyTZSSf5F7BXNwN42JWWvBvA4_GmktsAHn3tN9Bfwo_P55PTK67YT4w_l1Q--q5LhuMBVfF3HVio6U4JOpDJ2lMlCEUZdmlBzRqGwTkBTtQUhm8Nfrf6Vc1mnNb_2QwNB_NEXL6C68nZ9_EF72stcI8uf82jE5UNwalIIVVEIOFxLotKhUxmSlqB3Ksilxi8eh8ztAxFdEVdmSAxJgpevYZ9ZFq_ASZVsHXtpXZW66CtCzFzrvDG2-hcVAl82Ixyueiu1CjbrXCVlygNKoxZlCiNBD6SCEqaaSTwqj8wgFzozqryRFKsKo3Clsc7LXF4_Q55uCPELVfUqUzmqUngaCPVsp_Cq3KrcPj3f1ANev8cwV-RANuSiTElrTX1_HZVWqUypa1V9zTBaDw1ubEJHHba9LdzBKes0G_v7dwRPOnyGRRP82PYXy9v63cIk9Zu2E4BfObjdAgHp2eXV9_-AE40Ev4 |
link.rule.ids | 315,786,790,12083,12250,21416,27957,27958,31754,31755,33301,33302,33779,33780,43345,43614,43840,74102,74371,74659 |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Rb9MwED5BJxgSQlBghI3hBxBP1lLbsZMntE0rHWzVhDZpb1Fsx_DQpaXpkPbvuWvcokqwx-icnOU7330Xn-8APmSuRhRrNR-EVHKVe82rXAZeydQrlboUaZRtMdajK_X1OruOuTltTKtc2cSlofZTR__IDwT6WU19-z7PfnFqGkWHq7GDxkPYUhIjlR5sHZ2ML76vTbHpkg4RRqQckYyIme-pzA-mjeuqVapMbfikaJmfzqoWVyl07S3-jz-Xfmj4HJ5FAMkOO4m_gAd104dHXUvJuz5sH686uPXh8Xk8OH8JP06_DI8uuGQ_Me6cU9vouy4JjntUwd-1Z76mWhJ0EZMtb5MgBGU4pRkNaxgG5QQ0UUMYPjX4XntTTSac_vuzCRoM5og4fwVXw5PL4xGPPRa4Q1e_4MGmlfHeykChVEAA4XAPp5X0mcikMClyr4pcYNDqXMjQIhTBFnWlvcBYyDv5GnrItH4DTEhv6toJZY1SXhnrQ2Zt4bQzwdogE_i4WuVy1pXSKJdH4DIvURrUELMoURoJfCIRlLTDFvPKVfGiAHKhWlXloaAYVWiJI_c2RuLyug3y_oYQ11xRlzKRD3QCuyuplnHrtuVa0fDr_6Bq9Po5gr4iAbYmE2NKVmvq6W1bGikzqYyR9wzBKHygc20S2Om06e_kCEaZVL29d3LvYXt0eX5Wnp2Ov-3Cky6nQfJBvge9xfy2fodQaWH344b4A9SeETA |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LbxMxELagiIKEEIQCS0vxAcTJimN77d0TKoHQ8qh6oFJvKz_hEDYhmyL13zOTdVJFgh6jcTKW5_VNPJ4h5HXpI6BYp9kocclUFTSzlUzMSh6U4p4DDastTvXxufp8UV7klkJdLqtc-8SVow4zj_-RDwXEWY1z-4YpV0WcfZi8m_9mOEAKL1rzNI3b5A4ERYM2Wo2vqz1MX34IgIIzwDQi18BzWQ1nre_7VqpSbUWn7KMfzG0H55X6QRf_R6KriDR5RB5mKEmPetk_JrdiOyB3--GSVwNyb7ye5TYgu9_yFfoT8uPk0-T9GZP0J2SgCxwgfdWXw7EAyvgnBhoidpXAJ5l09a4EwCiFLc1xWUshPUfICbpC4VML3-t-2emU4Q0AnYLroB6Jiz1yPvn4fXzM8rQF5iHoL1ly3JoQnEyYVCWAEh6smVsZSlFKYThwt3UlIH31PpXgG-rk6mh1EJAVBS-fkh1gGp8TKmQwMXqhnFEqKONCKp2rvfYmOZdkQd6sT7mZ9001mtVluKwakAaOxqwbkEZB3qIIGrS15cJ6m58MABfsWtUcCcxWhZaw8mBrJRyv3yIfbglxwxW0qhTVSBdkfy3VJhtx12xUDn79H1QN8b8C-FcXhG7IyBjL1to4u-waI2UplTHyhiWQj490pU1BnvXadL05BFSGqxc3bu4V2QVLaL6enH7ZJ_f74gbJRtUB2VkuLuNLwExLd7iyhr_KihPK |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=IGFBP-3+hypermethylation-derived+deficiency+mediates+cisplatin+resistance+in+non-small-cell+lung+cancer&rft.jtitle=Oncogene&rft.au=Ibanez+de+Caceres%2C+I&rft.au=Cortes-Sempere%2C+M&rft.au=Moratilla%2C+C&rft.au=Machado-Pinilla%2C+R&rft.date=2010-03-18&rft.eissn=1476-5594&rft.volume=29&rft.issue=11&rft.spage=1681&rft.epage=1690&rft_id=info:doi/10.1038%2Fonc.2009.454&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0950-9232&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0950-9232&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0950-9232&client=summon |